← Back to Search

Procedure

Surgical Technique for Lung Cancer

N/A

Recruiting

Led By Tyler Grenda, MD

Research Sponsored by Thomas Jefferson University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC

Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing if a different order of cutting blood vessels during surgery for lung cancer could reduce the risk of the cancer coming back.

Who is the study for?

This trial is for adults over 18 with early-stage (I-III) non-small cell lung cancer, who are scheduled for routine lung surgery. It's not open to those with a recent cancer diagnosis within the last 5 years (with some exceptions), or patients who've had preoperative chemo, immunotherapy, radiation, or perioperative blood transfusions.Check my eligibility

What is being tested?

The study compares two surgical techniques used during lung resection surgery: pulmonary vein-first and pulmonary artery-first. The goal is to see which method better reduces circulating tumor DNA levels, potentially affecting long-term survival.See study design

What are the potential side effects?

Since this trial involves standard surgical procedures rather than new medications, side effects relate primarily to risks associated with lung surgery such as bleeding, infection, pain at the incision site and complications related to anesthesia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 or older with early-stage non-small cell lung cancer.

Select...

I am scheduled for a lung surgery to remove part of my lung.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

DNA

Secondary outcome measures

Disease free survival rate

Overall survival rate

Trial Design

2Treatment groups

Active Control

Group I: Group I (pulmonary vein first approach procedure)Active Control1 Intervention

Patients undergo pulmonary vein first approach surgical procedure on day of surgery.

Group II: Group II (pulmonary artery first surgical procedure)Active Control1 Intervention

Patients undergo pulmonary artery first approach surgical procedure on day of surgery.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor

445 Previous Clinical Trials

145,889 Total Patients Enrolled

Tyler Grenda, MDPrincipal InvestigatorTJU

Media Library

Pulmonary Artery-First Surgical Technique (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05502523 — N/A

Non-Small Cell Lung Cancer Research Study Groups: Group I (pulmonary vein first approach procedure), Group II (pulmonary artery first surgical procedure)

Non-Small Cell Lung Cancer Clinical Trial 2023: Pulmonary Artery-First Surgical Technique Highlights & Side Effects. Trial Name: NCT05502523 — N/A

Pulmonary Artery-First Surgical Technique (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05502523 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities to enroll in this research endeavor right now?

"Affirmative. The information on clinicaltrials.gov verifies that this investigation is presently enrolling subjects; the first posting appearing on August 31st 2022, with a recent update occuring two weeks later on September 14th 2022. It requires 100 volunteers from one site for successful completion."

Answered by AI

What is the total number of individuals that are eligible to participate in this clinical investigation?

"Affirmative. According to the information available on clinicaltrials.gov, this medical trial is open for recruitment presently. The initial posting was made on August 31st 2022 and it has been recently updated in mid-September of that same year. It aims to enrol 100 patients from one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

2022. "The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05502523.